Osteocytes are the most abundant cells in bone, making up roughly ninety percent of all bone cells, and they orchestrate the constant remodeling dialogue between bone formation and bone resorption. When glucocorticoid excess strikes, trabecular bone—the spongy lattice inside vertebrae and the ends of long bones—suffers the most visible early damage. But clinicians have long observed that cortical bone, the compact shell that provides most of the skeleton’s strength, also deteriorates under prolonged steroid exposure, and that this cortical thinning correlates strongly with nonvertebral fractures. The new research provides a mechanistic account of how the cells inside cortical bone are driven to self-destruction and how their demise translates directly into mineral loss from the surrounding matrix.

The investigative team used a well-established mouse model of glucocorticoid-induced osteoporosis, in which animals receive chronic prednisolone or methylprednisolone treatment sufficient to reproduce the human pattern of rapid bone loss. Using histomorphometry, micro-computed tomography, and dynamic bone labeling, they documented substantial cortical porosity, cortical thinning, and loss of mechanical integrity. Strikingly, the loss was accompanied by a marked depletion of osteocytes within the cortical compartment and by empty lacunae—minute cavities that once housed living cells—scattered throughout the cortex. This pattern suggested that osteocyte death itself, rather than merely elevated resorption by the classic bone-dissolving osteoclasts, might be a primary event in the pathology.

To define the mode of osteocyte death, the researchers examined the molecular machinery of necroptosis, a form of regulated necrosis distinguished from apoptosis by its explosive, membrane-rupturing character and its capacity to release intracellular contents that inflame surrounding tissue. Necroptosis is executed by a signaling complex in which receptor-interacting protein kinase 1 and receptor-interacting protein kinase 3 activate the executioner protein mixed lineage kinase domain-like pseudokinase, or MLKL, which oligomerizes and punches holes in the cell membrane. In the steroid-treated mice, the team found robust activation of this pathway specifically in cortical osteocytes: phosphorylated RIPK3 and phosphorylated MLKL accumulated within lacunar cells, while markers of apoptosis were comparatively modest. Genetic or pharmacological interference with the pathway therefore became the decisive test of causality.

When the researchers crossed their glucocorticoid-treated mice with animals lacking functional MLKL, or when they treated mice with a selective RIPK1 kinase inhibitor, the picture changed dramatically. Cortical bone loss was substantially attenuated: cortical thickness was preserved, porosity declined, and biomechanical testing showed that bones retained significantly more of their strength compared with steroid-treated controls carrying intact necroptosis machinery. Osteocyte lacunae remained populated, and the hallmarks of inflammatory cell death faded. Inhibiting apoptosis, by contrast, produced only modest skeletal protection, reinforcing the conclusion that necroptosis is the dominant death program through which glucocorticoids destroy the osteocyte network in cortical bone.

The most provocative element of the study is the mechanism the authors propose for how dying osteocytes cause resorption of the mineral that surrounds them. Under normal physiological conditions, osteocytes can participate in a process called osteocytic osteolysis, in which stressed or starved osteocytes demineralize and degrade their own perilacunar matrix, releasing calcium and remolding their immediate microenvironment. The study demonstrates that necroptotic death converts this finely regulated process into a destructive free-for-all. As necroptotic osteocytes rupture, they release damage-associated molecular patterns and lysosomal enzymes that acidify the perilacunar space and dissolve the adjacent mineralized collagen matrix. In essence, each dying cell excavates the bone around it, generating the microscopic porosity that, when multiplied across millions of lacunae, hollows out the cortex from within.

Supporting this mechanism, the researchers tracked perilacunar remodeling with dynamic imaging and found that steroid exposure dramatically expanded the demineralized halos around individual lacunae, a signature of aggressive osteocytic osteolysis. They also showed that products released from necroptotic osteocytes could recruit and activate osteoclast precursors, coupling the internal excavation to conventional resorption on bone surfaces. This dual mechanism—autolytic matrix degradation by the dying cells themselves followed by secondary osteoclast activation—offers a coherent explanation for the peculiar severity and speed of glucocorticoid-induced cortical loss, which has never been fully accounted for by osteoclast activity alone.

The clinical implications are considerable. Current management of glucocorticoid-induced osteoporosis relies on calcium and vitamin D supplementation and antiresorptive agents such as bisphosphonates, which dampen osteoclast function but do nothing to protect osteocytes from dying. If necroptosis inhibition shields osteocytes from steroid toxicity in humans as it does in mice, a fundamentally new class of preventive therapy becomes conceivable: drugs that preserve the cellular network inside bone, maintaining the mechanosensory and regulatory functions that keep remodeling balanced, while simultaneously stemming the perilacunar erosion that undermines cortical strength. Inhibitors targeting the RIPK1–RIPK3–MLKL axis are already in clinical development for inflammatory and neurodegenerative diseases, which could accelerate translation into skeletal medicine.

The authors are careful to frame their conclusions within the limits of the model system. Necroptosis is a context-dependent process, and its contribution to bone loss may vary with dose, duration of steroid exposure, age, and species. Human bone biopsies from patients on long-term glucocorticoid therapy will be needed to confirm that the same molecular signature of phosphorylated MLKL and perilacunar demineralization appears in cortical osteocytes in vivo. Nonetheless, the convergence of genetic, pharmacological, and structural evidence in this study provides an unusually complete causal chain, linking a specific cell death program to a specific mode of matrix destruction and to a measurable functional outcome in the skeleton.

Beyond the immediate therapeutic horizon, the work reframes how scientists think about the skeleton’s response to stress. Osteocytes, once viewed as inert placeholders, are now firmly established as the command centers of bone, and their death by necroptosis represents a catastrophic failure of that command infrastructure. The finding that the same cells whose death is triggered by steroid excess then participate in dismantling their own mineralized surroundings blurs the boundary between cell death and bone resorption, suggesting that in disease states the two processes are woven together. For the millions of patients worldwide who depend on glucocorticoids, the study offers a concrete molecular target for keeping their skeletons intact—and a reminder that some of the most important cells in bone are the ones buried deepest inside it.

Subject of Research: Necroptosis of osteocytes as a mechanism of cortical bone resorption in glucocorticoid-induced osteoporosis

Article Title: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis

Article References: Osteocyte necroptosis drives cortical bone resorption via osteocytic osteolysis in glucocorticoid-induced osteoporosis. (n.d.). https://doi.org/10.1038/s41420-026-03329-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03329-y

Keywords: osteocytes, necroptosis, glucocorticoid-induced osteoporosis, cortical bone, osteocytic osteolysis, MLKL, RIPK3, bone resorption, osteoclasts, perilacunar remodeling, Cell Death Discovery, bone fractures

Inflammatory bowel disease affects millions of people worldwide, and its hallmark is a self-perpetuating loop of tissue damage. Barrier breakdown in the intestinal epithelium allows microbial products to flood the underlying tissue, where resident macrophages respond by releasing cytokines that recruit and activate further immune cells. When this response fails to resolve, the mucosa becomes a chronic battlefield. Current therapies, including corticosteroids, anti-TNF antibodies, and integrin blockers, help many patients but lose effectiveness in a substantial fraction, which is why researchers continue to search for checkpoints within innate immune cells that could be exploited pharmacologically.

The new work focuses on PANoptosis, an inflammatory form of programmed cell death that has attracted intense attention since it was first defined. Unlike apoptosis, which quietly removes cells without alarming the immune system, PANoptosis combines features of pyroptosis, apoptosis, and necroptosis in a single, highly inflammatory package. At its core sits a multiprotein assembly called the PANoptosome, which in many contexts is organized around the sensor protein ZBP1, a nucleic acid receptor better known for detecting viral RNA. When ZBP1 is engaged, it recruits RIPK3, caspase-8, and other partners, driving cells to die in a way that releases danger signals and amplifies inflammation. Uncontrolled ZBP1-driven PANoptosis has been implicated in several sterile inflammatory diseases, making it a tempting but delicate target.

Using mouse models of colitis, the research team found that NINJ2 expression in intestinal macrophages changed markedly as inflammation developed. When the researchers deleted the Ninj2 gene specifically in myeloid cells, the animals fared substantially worse: colitis induced by dextran sulfate sodium produced greater weight loss, more pronounced colon shortening, higher histological damage scores, and elevated levels of pro-inflammatory cytokines such as TNF, IL-1β, and IL-6. The worsened disease was not simply a matter of more macrophages arriving in the tissue. Instead, the macrophages that remained appeared locked into a hyperinflammatory state, suggesting that NINJ2 normally functions as an intrinsic regulator of how these cells respond to danger.

The mechanistic thread connecting NINJ2 to disease severity ran directly through the ZBP1 pathway. In macrophages lacking NINJ2, the investigators documented increased activation of the molecular machinery of PANoptosis, including enhanced phosphorylation of RIPK3 and mixed lineage kinase domain-like protein, the executioner of necroptosis, together with evidence of caspase activation and gasdermin cleavage. Levels of ZBP1 itself rose in the absence of NINJ2, and the assembly of the PANoptosome appeared more robust. Conversely, when the team reduced ZBP1 genetically in the NINJ2-deficient setting, the exaggerated inflammatory response was tamed and colitis pathology eased, placing ZBP1 downstream of NINJ2 in the causal chain and confirming that the benefit of NINJ2 depends on keeping this sensor in check.

To probe how NINJ2 accomplishes this restraint, the researchers examined transcriptional regulation. Their data indicate that NINJ2 influences the expression of ZBP1 at the level of messenger RNA, effectively lowering the dose of the danger sensor available to assemble into a PANoptosome. This dose-control mechanism matters because ZBP1 is unusual among innate immune receptors: it can be activated not only by foreign RNA but also by endogenous nucleic acid motifs, meaning that even modest increases in its abundance can lower the threshold for spontaneous inflammatory cell death. By holding ZBP1 transcription down, NINJ2 appears to act as a dimmer switch on an otherwise hair-trigger pathway.

Cell culture experiments reinforced the picture. When macrophages were stimulated with inflammatory ligands, those lacking NINJ2 died more readily and secreted more cytokines, while restoring NINJ2 expression rescued both outcomes. The rescue was abolished when ZBP1 was experimentally elevated, underlining the epistatic relationship between the two proteins. The team also observed that the PANoptosome components physically associated more extensively in NINJ2-deficient cells, consistent with a model in which NINJ2 limits both the quantity of ZBP1 and the downstream assembly of the death complex. Together, the in vivo and in vitro results form a coherent loop: NINJ2 restrains ZBP1, restrained ZBP1 limits PANoptosis, and limited PANoptosis means fewer danger signals to perpetuate intestinal inflammation.

What makes the discovery particularly striking is NINJ2’s résumé. The protein was originally characterized in the nervous system, where it is strongly upregulated in Schwann cells after peripheral nerve injury and contributes to axonal regeneration and remyelination. Its presence in macrophages had been noted, but its immunological function was largely unexplored. The new data suggest a broader physiological role in which the same molecule that helps damaged nerves recover also helps immune tissue recover from inflammatory assault. That kind of cross-system redeployment is increasingly common in immunology, where molecules first discovered in one organ are later found to be central choreographers of innate immune behavior elsewhere.

The therapeutic implications are tentative but concrete. If NINJ2’s protective effect can be mimicked, either by small molecules that increase its expression in intestinal macrophages or by delivery systems that supply the protein or its downstream effectors, patients with inflammatory bowel disease might gain a treatment that works at the source of cytokine storm rather than neutralizing individual cytokines after release. Targeting upstream regulators also carries risks, however. PANoptosis serves host defense, particularly against viruses, so wholesale suppression could impair pathogen clearance. The NINJ2-ZBP1 axis is attractive precisely because it appears to modulate the pathway’s set point rather than abolish it, but any clinical translation would need to define carefully how much damping is safe. Biomarkers of NINJ2 expression in patient biopsies could help identify which individuals are most likely to benefit.

Open questions remain. The precise molecular contacts, if any, between NINJ2 and the transcriptional machinery governing ZBP1 have not been fully mapped, and it is not yet clear whether NINJ2 acts directly on the ZBP1 promoter or through intermediate regulators. It is also unknown whether the pathway operates identically in human intestinal macrophages, which differ from their murine counterparts in several respects. Nonetheless, by connecting a nerve-associated protein to the ZBP1-PANoptosis cascade in the gut, the study adds a new node to the network that decides when macrophages choose inflammatory death, and it offers researchers a fresh candidate for intervention in a disease that still lacks a durable cure for many patients. Follow-up work will determine whether raising NINJ2 in the inflamed intestine can turn that candidate into a therapy.

Subject of Research: The role of NINJ2 in regulating macrophage ZBP1-PANoptosis during inflammatory bowel disease

Article Title: NINJ2 alleviates inflammatory bowel disease by regulating the macrophage ZBP1-PANoptosis pathway

Article References: Peng, H., Yu, Y., Du, Y., Guo, X., Yu, Q., Xu, C., & Song, W. (2026). NINJ2 alleviates inflammatory bowel disease by regulating the macrophage ZBP1-PANoptosis pathway. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03353-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03353-y

Keywords: NINJ2, inflammatory bowel disease, PANoptosis, ZBP1, macrophages, colitis, innate immunity, cell death, cytokines, intestinal inflammation, RIPK3, Schwann cells

Necroptosis and ferroptosis are distinct biological programs, but both can culminate in catastrophic loss of plasma-membrane integrity and the release of inflammatory intracellular contents. Necroptosis is a kinase-driven form of regulated necrosis that is typically associated with the receptor-interacting protein kinase 1, receptor-interacting protein kinase 3, and mixed lineage kinase domain-like pseudokinase axis. In response to signals such as tumor necrosis factor, pathogen-associated stress, damage-associated molecular patterns, or certain chemical insults, RIPK1 and RIPK3 can assemble into a signaling platform known as the necrosome. This promotes phosphorylation and oligomerization of MLKL, which then moves to the plasma membrane and disrupts its architecture. The resulting cellular rupture can release damage-associated molecular patterns and amplify local inflammation.

Ferroptosis follows a different molecular route. It is driven by iron-dependent oxidative damage to membrane lipids, particularly phospholipids containing polyunsaturated fatty acids. When intracellular iron availability and reactive oxygen species increase, susceptible lipids can undergo a chain reaction of peroxidation. Under normal conditions, antioxidant systems limit this process. Glutathione peroxidase 4 is one of the principal defenses because it reduces toxic lipid hydroperoxides to less-reactive lipid alcohols. Ferroptosis suppressor protein 1 provides another protective mechanism by supporting the regeneration of reduced coenzyme Q10, a radical-trapping antioxidant. When these systems are overwhelmed or disabled, lipid peroxide accumulation destabilizes membranes and can ultimately produce irreversible cell damage.

Although the initiating signals differ, the two pathways can be influenced by overlapping cellular conditions. Redox imbalance, mitochondrial dysfunction, altered lipid metabolism, iron handling, and inflammatory signaling may affect both necroptotic and ferroptotic sensitivity. In some disease settings, suppression of one form of regulated death may also shift cellular stress toward another. This possibility is particularly important in acute and chronic organ injuries, where damaged tissues may contain multiple cell populations exposed to cytokines, hypoxia, metabolic disruption, and oxidative stress at the same time. According to the review, these interconnections create a rationale for investigating compounds that can modulate more than one regulated-death mechanism.

The NecroFerrin concept is based on combining two pharmacological activities within a single molecular framework. One activity would interfere with necroptotic signaling, potentially by inhibiting RIPK1-dependent events. The second would limit the propagation of lipid radicals and thereby reduce ferroptotic membrane damage. The review highlights RIPROStatins as an example of this strategy. These compounds are described as combining RIPK1 inhibition with radical-trapping antioxidant properties, bringing together suppression of a protein-kinase-controlled pathway and chemical interception of the lipid oxidation reactions that drive ferroptosis. Such a design is intended to address both upstream signaling and downstream membrane injury.

The proposed mechanism also involves molecular systems that connect protein quality control with oxidative cell death. The review discusses heat shock protein 90 as one example of a cellular chaperone that can influence these pathways. HSP90 helps stabilize and regulate numerous proteins, and it may participate in chaperone-mediated autophagic degradation of GPX4 under certain conditions. Because GPX4 is central to the removal of lipid peroxides, changes in its abundance or activity can strongly affect ferroptotic vulnerability. This relationship illustrates why a compound’s effects may extend beyond a single signaling protein: cellular chaperones, autophagy, antioxidant capacity, iron metabolism, and membrane composition can collectively determine whether a stressed cell survives or crosses the threshold into regulated necrosis.

The review places NecroFerrins within the broader field of polypharmacology, which seeks to use one compound to influence several biologically connected targets. In complex diseases, single-target drugs may be limited by pathway redundancy, compensatory signaling, or the simultaneous activation of multiple injury programs. A molecule that blocks RIPK1-dependent necroptosis while also neutralizing lipid radicals could, in principle, provide broader protection than either a selective necroptosis inhibitor or a ferroptosis inhibitor alone. However, the authors emphasize that dual activity does not automatically translate into therapeutic success. The balance between potency, selectivity, tissue distribution, metabolic stability, and toxicity will determine whether such molecules can be developed into useful treatments.

This caution is especially relevant because necroptosis and ferroptosis are not exclusively harmful processes in every biological context. Regulated cell death contributes to host defense, tissue remodeling, elimination of damaged cells, and responses to infection. Broadly suppressing these mechanisms could therefore interfere with beneficial immune or homeostatic functions. In addition, the same compound may behave differently across organs because cells vary in their expression of RIPK1, RIPK3, MLKL, GPX4, FSP1, antioxidant enzymes, iron-storage proteins, and lipid-processing pathways. Rigorous studies will be required to establish whether a candidate NecroFerrin acts through the intended mechanisms in living tissues and whether it can protect organs without producing undesirable immunological or metabolic effects.

The authors present the dual-inhibition concept as a framework for future chemical biology rather than as a completed therapeutic solution. Experimental validation will need to distinguish direct pathway inhibition from nonspecific antioxidant or cytoprotective effects. Researchers will also need to determine how these molecules perform in disease models involving ischemia-reperfusion injury, inflammation, infection, neurodegeneration, or organ fibrosis, where regulated cell-death pathways may operate simultaneously. Biomarkers of necroptosis, ferroptosis, lipid peroxidation, iron status, and inflammatory damage could help identify patients or disease stages most likely to benefit. By viewing regulated cell death as an interconnected network, the review argues that future drug discovery may move beyond the question of how to inhibit one pathway and instead ask whether several converging mechanisms can be controlled with a carefully designed single molecule.

Subject of Research: Cells

Article Title: NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis

Web References: https://doi.org/10.70401/fos.2026.0041 ; https://smart.servier.com/ ; https://creativecommons.org/licenses/by/4.0/

References: Delehouzé, Claire, and Stéphane Bach. “NecroFerrins as dual therapeutic inhibitors targeting necroptosis and ferroptosis.” Ferroptosis and Oxidative Stress. DOI: 10.70401/fos.2026.0041.

Image Credits: Claire Delehouzé and Stéphane Bach, 2027; adapted from Servier Medical Art, licensed under CC BY 4.0.

Keywords: Necroptosis, ferroptosis, NecroFerrins, RIPK1, RIPK3, MLKL, lipid peroxidation, GPX4, FSP1, oxidative stress, regulated cell death, polypharmacology, RIPROStatins